Homology Medicines to Participate in Panel on Genetic Medicines at 2017 BIO International Convention

BEDFORD, Mass., June 19, 2017 – Homology Medicines, Inc., a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients, announced today that Company management will participate in the panel, “Will the Challenges of Delivering the Personalized Genetic Medicines of Tomorrow Outweigh the Promise of Today?” during the 2017 BIO International Convention at 9:00 a.m. PT on Thursday, June 22 at the San Diego Convention Center.

About Homology Medicines, Inc.

Homology Medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The combination of a new multidimensional technology platform and a management team that has successfully developed and commercialized rare disease therapies uniquely positions the Company to move beyond the current limitations of gene therapy and gene editing approaches to improve patient care. Homology has built foundational intellectual property on gene editing and gene therapy using vectors derived from naturally occurring human adeno-associated viruses (AAVs). The Company’s technology is precise, on-target and highly efficient for in vivo editing of genetic mutations. The unique team and technology create a significant opportunity for Homology to rapidly advance a diverse pipeline of new medicines that address and potentially cure the underlying cause of genetic diseases. For more information, please visit www.homologymedicines.com.

Cara Mayfield
Director, Corporate Communications
cmayfield@homologymedicines.com
781-301-7277, ext. 141

< BACK